ライフサイエンスコーパス: liver cirrhosis

1 ing used for cell therapies of patients with liver cirrhosis.

2 poietic stem-cell infusions in patients with liver cirrhosis.

3 wo hundred eleven patients of the cohort had liver cirrhosis.

4 rent serum samples of (MHE) in patients with liver cirrhosis.

5 cellular carcinoma (HCC) in well-compensated liver cirrhosis.

6 this approach has potential for treatment of liver cirrhosis.

7 ation, which are defining characteristics of liver cirrhosis.

8 n and hemostasis are common in patients with liver cirrhosis.

9 s a common, life-threatening complication of liver cirrhosis.

10 rs (hepatocarcinogenesis) concomitantly with liver cirrhosis.

11 including chronic hepatitis and compensated liver cirrhosis.

12 ing autophagy may hold therapeutic value for liver cirrhosis.

13 mation, fatty liver, alcoholic hepatitis, or liver cirrhosis.

14 onsible for compromised Nrf2 response during liver cirrhosis.

15 athological importance of this cross-talk in liver cirrhosis.

16 han Keap1, to prevent Nrf2 loss and suppress liver cirrhosis.

17 tion of chronic inflammation that has led to liver cirrhosis.

18 infected cohort with comparable frequency of liver cirrhosis.

19 scites is a major and common complication of liver cirrhosis.

20 ritonitis, which is a common complication of liver cirrhosis.

21 erapy for patients with "early-stage" HCC on liver cirrhosis.

22 one factor in the pathogenesis of alcoholic liver cirrhosis.

23 serve as markers of disease and prognosis in liver cirrhosis.

24 ing an invasion of the gut from the mouth in liver cirrhosis.

25 implicated in the pathogenesis of alcoholic liver cirrhosis.

26 nal strategy to delay disease progression in liver cirrhosis.

27 uitable and large source for cell therapy of liver cirrhosis.

28 triple therapy, especially in patients with liver cirrhosis.

29 options differ from those for patients with liver cirrhosis.

30 (HCC) occurs predominantly in patients with liver cirrhosis.

31 n is a serious complication in patients with liver cirrhosis.

32 fied according to the presence or absence of liver cirrhosis.

33 on-cirrhotic liver disease and patients with liver cirrhosis.

34 brosis, bone marrow failure, and cryptogenic liver cirrhosis.

35 n-cirrhotic liver disease and 158 (0.4%) had liver cirrhosis.

36 ies such as Alzheimer's disease, cancer, and liver cirrhosis.

37 th amount and glycosylation as a function of liver cirrhosis.

38 chronic hepatitis B (CHB) in the absence of liver cirrhosis.

39 excessive scarring and organ failure, as in liver cirrhosis.

40 better overview of the coagulation system in liver cirrhosis.

41 IV/HCV)-coinfected patients with compensated liver cirrhosis.

42 ous neurologic complication in patients with liver cirrhosis.

43 translocation and infection in patients with liver cirrhosis.

44 attention deficits and MHE in patients with liver cirrhosis.

45 risk of liver-related death in patients with liver cirrhosis.

46 ult in novel therapeutic approaches to treat liver cirrhosis.

47 in a patient with refractory ascites due to liver cirrhosis.

48 matrix production and portal hypertension in liver cirrhosis.

49 vein and signs of portal hypertension due to liver cirrhosis.

50 nt of overt HE and survival in patients with liver cirrhosis.

51 discovery of rational therapeutic targets in liver cirrhosis.

52 rm mortality in critically ill patients with liver cirrhosis.

53 h meals, daily frequency of consumption, and liver cirrhosis.

54 BV infection results in rapid progression to liver cirrhosis.

55 ice after BDL and in patients suffering from liver cirrhosis.

56 otein inclusions, causing lung emphysema and liver cirrhosis.

57 f hepatocellular nodules in individuals with liver cirrhosis.

58 ophageal varices is a deadly complication of liver cirrhosis.

59 ing by screening all patients diagnosed with liver cirrhosis.

60 liver infections other than HBV and HDV, or liver cirrhosis.

61 e course, but some had immunosuppression and liver cirrhosis.

62 redictors of the absolute risk for alcoholic liver cirrhosis.

63 py for liver cancer stem cells together with liver cirrhosis.

64 system, similar to the Child-Pugh-Score for liver cirrhosis.

65 es of 21 outcomes (8 primary liver cancer, 1 liver cirrhosis, 10 viral replication and 2 liver inflam

66 the ascites samples from the volunteers with liver cirrhosis, 50% contained bacterial DNA from Entero

67 than angiodysplasia patients had co-existing liver cirrhosis (63.2% versus 25.9%, P = 0.012).

68 We included 15 patients with liver cirrhosis (8 Child-Pugh A, 6 Child-Pugh B, and 1 C

69 been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC.

70 transplantation in clinical trials, to treat liver cirrhosis, an irreversible disease that may eventu

71 ion profiles in 76 patients with HBV-related liver cirrhosis and 115 patients with chronic hepatitis

72 9% (n = 18) of these patients presented with liver cirrhosis and 58% (n = 15) were treatment experien

73 (HCV) infections account for 57% of cases of liver cirrhosis and 78% of cases of primary liver cancer

74 c magnetic resonance imaging (MRI) diagnosed liver cirrhosis and a segment 7/8 lesion measuring 4 cm,

75 value of lactate is not well established in liver cirrhosis and acute-on-chronic liver failure (ACLF

76 pective observational study in patients with liver cirrhosis and an indication for fluoroquinolone-ba

77 escribe a case of a 50-year-old patient with liver cirrhosis and APF, probably formed as a result of

78 apenems on 30-day mortality of patients with liver cirrhosis and bloodstream infection (BSI).

79 ous insults and is a platform for developing liver cirrhosis and cancer.

80 virus (HCV) infection is a leading cause of liver cirrhosis and cancer.

81 (HCV) is a widespread human pathogen causing liver cirrhosis and cancer.

82 hepatitis C virus (HCV) is a common cause of liver cirrhosis and cancer.

83 Most patients with HCC have underlying liver cirrhosis and compromised liver function, limiting

84 lic steatohepatitis, ultimately resulting in liver cirrhosis and failure.

85 sis, group-IV: patients with chronic HCV and liver cirrhosis and group-V: Age and sex matched healthy

86 ns, in healthy individuals and patients with liver cirrhosis and HCC.

87 ned unchanged in the brains of patients with liver cirrhosis and HE compared with controls.

88 also apply to human brain from patients with liver cirrhosis and HE.

89 ated in the cerebral cortex of patients with liver cirrhosis and HE.

90 ber 2018 to December 2019, participants with liver cirrhosis and healthy control participants underwe

91 e hepatitis B virus (HBV)-the major cause of liver cirrhosis and hepatocellular carcinoma (HCC).

92 antigen seroconversion and increased risk of liver cirrhosis and hepatocellular carcinoma (HCC).

93 C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma and the lea

94 eroconversion, and an increased incidence of liver cirrhosis and hepatocellular carcinoma compared wi

95 ent was a 51-year-old man with decompensated liver cirrhosis and hepatocellular carcinoma.

96 ted worldwide, and are at risk of developing liver cirrhosis and hepatocellular carcinoma.

97 s progressive and is a major cause of severe liver cirrhosis and hepatocellular carcinoma.

98 disease and associated complications such as liver cirrhosis and hepatocellular carcinoma.

99 te and chronic hepatitis with a high risk of liver cirrhosis and hepatocellular carcinoma.

100 Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma.

101 nfection often results in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.

102 causes hepatic inflammation and can lead to liver cirrhosis and hepatocellular carcinoma.

103 ople worldwide and are significant causes of liver cirrhosis and hepatocellular carcinoma.

104 alth issue, predispose to the development of liver cirrhosis and hepatocellular carcinoma.

105 c infection, and the eventual development of liver cirrhosis and hepatocellular carcinoma.

106 HBV) is associated with rapid progression to liver cirrhosis and hepatocellular carcinoma.

107 health problem because it is a main cause of liver cirrhosis and hepatocellular carcinoma.

108 d chronic liver infection, which may lead to liver cirrhosis and hepatocellular carcinoma.

109 bidity and mortality due to complications of liver cirrhosis and hepatocellular carcinoma.

110 of the leading causes of chronic hepatitis, liver cirrhosis and hepatocellular carcinomas and infect

111 The rat models with liver cirrhosis and HPS were induced by multiple pathoge

112 The rat model of liver cirrhosis and HPS were induced with multiple patho

113 ly, HEV-HIV coinfection leads to accelerated liver cirrhosis and increased mortality rates compared t

114 ith compared to patients without established liver cirrhosis and increased with the Child-Pugh stage

115 Renal dysfunction is frequent in liver cirrhosis and is a strong prognostic predictor of

116 halopathy (HE) is a frequent complication of liver cirrhosis and is seen as the clinical manifestatio

117 develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time.

118 develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time.

119 Patients who have liver cirrhosis and liver cancer also have reduced farne

120 (e.g., blood donation) and cause hepatitis, liver cirrhosis and liver cancer.

121 ction is associated with fast progression to liver cirrhosis and liver complications.

122 in the portal venous system of patients with liver cirrhosis and may be a means of assessing patholog

123 tals and recruited patients with compensated liver cirrhosis and MELD scores of 11.0-15.5.

124 titis (72.1%), followed by cholelithiasis in liver cirrhosis and portal hypertension (18.2%) and empy

125 Patients with liver cirrhosis and portal hypertension demonstrated fas

126 rectal motility and transit in patients with liver cirrhosis and portal hypertension using a magnet-b

127 ably due to the high number of patients with liver cirrhosis and prior treatment experience, treatmen

128 on strategies in patients with decompensated liver cirrhosis and SBP.

129 astric varices (GV) associated with advanced liver cirrhosis and severe portal hypertension.

130 ent for hemodynamic and renal alterations of liver cirrhosis and should be tested in cirrhosis patien

131 g to colorectal cancer, type 2 diabetes, and liver cirrhosis and show that including reads from unkno

132 the mechanisms of hepatocyte dysfunction in liver cirrhosis and spur development of novel treatments

133 HCCs only occurred secondary to liver cirrhosis and their event rates in this cohort of

134 AP activity in human patients diagnosed with liver cirrhosis and to determine the effectiveness of a

135 Hh was upregulated in experimental and human liver cirrhosis and was blunted by atorvastatin.

136 and 600,000 annual deaths due to HBV-induced liver cirrhosis and/or hepatocellular carcinoma, chronic

137 nic liver diseases, radiological evidence of liver cirrhosis, and compensated liver function.

138 nvolved in steroid/cholesterol biosynthesis, liver cirrhosis, and connective tissue disease.

139 nt in ascites of patients with decompensated liver cirrhosis, and focus especially on MAIT cells.

140 itoring transcript changes in healthy liver, liver cirrhosis, and HCC with viral and alcoholic etiolo

141 leading cause of chronic hepatitis C (CHC), liver cirrhosis, and hepatocellular carcinoma (HCC).

142 (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma in humans.

143 causative factor of chronic viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

144 ivirus, is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

145 putting them at risk for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

146 ologic with an undisputed link to hepatitis, liver cirrhosis, and hepatocellular carcinoma.

147 C virus (HCV) can lead to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

148 HBV is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

149 262 patients with PA, 117 with SA because of liver cirrhosis, and in 61 control healthy subjects.

150 n various clinical disorders such as trauma, liver cirrhosis, and leukemia.

151 scular diseases, COPD, most forms of cancer, liver cirrhosis, and maternal disorders.

152 enance and repair cause bone marrow failure, liver cirrhosis, and pulmonary fibrosis, and they increa

153 and aplastic anemia, acute myeloid leukemia, liver cirrhosis, and pulmonary fibrosis.

154 diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis.

155 s, chronic lower respiratory tract diseases, liver cirrhosis, and spinal disc herniation); causes of

156 h early AATD, and among patients with normal liver, cirrhosis, and hepatocellular carcinoma derived f

157 Our study showed that younger patients with liver cirrhosis are characterised by wider paraumbilical

158 Patients with liver cirrhosis are particularly vulnerable to its devel

159 studies of bone marrow (BM) cell therapy for liver cirrhosis are under way but the mechanisms of bene

160 portion of patients with chronic HCV develop liver cirrhosis as a consequence of heavy alcohol use.

161 hepatitis C virus (HCV)-related compensated liver cirrhosis, as well as the predictors of response i

162 various body fluids such as amniotic fluid, liver cirrhosis ascites, and malignant ascites of ovaria

163 pathy, and angiogenesis with the severity of liver cirrhosis (assessed by the Child-Pugh-Turcotte sco

164 The patients of liver cirrhosis associated with portal vein thrombosis (

165 t, 9.3% of patients showed clinical signs of liver cirrhosis at 35 years after infection.

166 Biomarkers specific to liver cirrhosis at gene and function levels are revealed

167 ve, and treatment-naive participants without liver cirrhosis at study entry were included.

168 Individuals with preexisting jaundice or liver cirrhosis at the time of admission (n = 31) were e

169 hepatitis C virus, alcoholic liver disease, liver cirrhosis, biliary cirrhosis, hemochromatosis, Wil

170 Age >50 years, liver cirrhosis, bilirubin >1.1 mg/dl (P < 0.01, each),

171 Liver cirrhosis but also portal vein obstruction cause p

172 erapy is safe and effective in patients with liver cirrhosis, but no adequately powered randomised co

173 nt prediction roles in colorectal cancer and liver cirrhosis, but not in type 2 diabetes.

174 ntigen (vWF-Ag) is elevated in patients with liver cirrhosis, but the clinical significance is unclea

175 ial morbidity and mortality in patients with liver cirrhosis, but their long-term risk of recurrent b

176 with CCl(4)-induced portal hypertension and liver cirrhosis, but were normal in other rodent models

177 Here we characterize the gut microbiome in liver cirrhosis by comparing 98 patients and 83 healthy

178 Emphysema and liver cirrhosis can be caused by the Z mutation (Glu342L

179 xpression was observed in human specimens of liver cirrhosis caused by both hepatitis C and steatohep

180 Two patients with advanced liver cirrhosis (Child-Pugh C) have been submitted to th

181 oblems had a much greater risk for alcoholic liver cirrhosis compared to the general population.

182 Portal vein hypertension (PVH) in liver cirrhosis complicated with portal venous thrombosi

183 ed severe liver disease outcomes (defined as liver cirrhosis, complications of cirrhosis, or liver-re

184 dysfunction) were related to the severity of liver cirrhosis (CTP score), mainly IP-10 and IL-6, whic

185 During follow-up, complications of liver cirrhosis, death or transplantation were recorded.

186 ms in pooled plasma samples of patients with liver cirrhosis detects reliably the expected changes in

187 r dependence) during 1998-2002 for alcoholic liver cirrhosis development (n = 36,044).

188 ive parenchymal iron accumulation leading to liver cirrhosis, diabetes, and in some cases hepatocellu

189 safe in most patients (94%), a patient with liver cirrhosis died of multiorgan failure secondary to

190 control participants, the participants with liver cirrhosis displayed reduced longitudinal strain an

191 ients with chronic liver diseases apart from liver cirrhosis, especially in NAFLD.

192 A substantial baseline risk of liver cirrhosis exists for patients with chronic hepatit

193 Liver cirrhosis has been associated with decreased absol

194 epatitis C virus (HCV) infection even before liver cirrhosis has developed.

195 n faecal bacterial populations and alcoholic liver cirrhosis has not been resolved.

196 Patients with advanced liver cirrhosis have an increased susceptibility to infe

197 oves liver function in a clinically relevant liver cirrhosis/HCC model.

198 bidity and mortality due to complications of liver cirrhosis, hepatic decompensation, and hepatocellu

199 SVR is associated with a reduced risk of liver cirrhosis, hepatic decompensation, need for liver

200 global population and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and end-stage

201 lion individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality

202 e at initiation of chronic HBV infection and liver cirrhosis, hepatocellular carcinoma, and their pre

203 ated tumor (HR 3.18 [range, 1.31-7.70]), and liver cirrhosis (HR 1.90 [range, 1.04-3.12]).

204 ic syndrome is an independent risk factor of liver cirrhosis in chronic hepatitis B (CHB).

205 the prediction of mortality in patients with liver cirrhosis in clinical practice.

206 might be a potentially useful drug to treat liver cirrhosis in clinical practice.

207 one (GH) resistance has been associated with liver cirrhosis in humans but its contribution to the di

208 l of cardiovascular factors in patients with liver cirrhosis in order to avoid associated thrombosis.

209 Background Cardiac involvement in liver cirrhosis in the absence of underlying cardiac dis

210 The IRR for alcoholic liver cirrhosis in the cohort relative to the general po

211 to increased bleeding risk in patients with liver cirrhosis in the intensive care unit, and fibrinog

212 estimated as the incidence rate of alcoholic liver cirrhosis in these patients relative to the genera

213 patients with compensated and decompensated liver cirrhosis in two groups with completely different

214 epatitis C virus (HCV) infection can lead to liver cirrhosis in up to 20% of individuals, often requi

215 The authors present a patient with liver cirrhosis, in whom percutaneous APF closure facili

216 topic HCC model in immunocompetent mice with liver cirrhosis induced by carbon tetrachloride (CCl4) t

217 Liver cirrhosis is a major cause of death worldwide and

218 Liver cirrhosis is associated with bacterial translocati

219 hronic liver failure (ACLF) in patients with liver cirrhosis is associated with high mortality rates.

220 Liver cirrhosis is associated with long-term risk of rec

221 ngitis have a poor prognosis; progression to liver cirrhosis is common, and an increased risk of hepa

222 Acute anaemia in decompensated liver cirrhosis is commonly caused due to gastrointestin

223 BACKGROUND & AIMS: Liver cirrhosis is complicated by bleeding from portal h

224 ve capabilities of the method and shows that liver cirrhosis is consistently associated with increase

225 imaging at 1.5 T to detect and assess human liver cirrhosis is feasible.

226 sma fatty acid (FA) pattern in patients with liver cirrhosis is fragmentary.

227 patitis C virus (HCV)-infected patients with liver cirrhosis is not fully known.

228 Liver cirrhosis is one of the main causes of death and d

229 Cardiac dysfunction in patients with liver cirrhosis is strongly associated with increased se

230 r disease is rising in western countries and liver cirrhosis is the 12th leading cause of death world

231 Liver cirrhosis is the most important risk factor for he

232 Alcoholic liver cirrhosis is usually preceded by many years of hea

233 on (PH), a pathophysiological derangement of liver cirrhosis, is characterized by hyperdynamic circul

234 tis C virus infection with a greater risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC).

235 hepatitis C (CHC), which often progresses to liver cirrhosis (LC) and hepatocellular carcinoma (HCC).

236 Recent studies have shown that liver cirrhosis (LC) behaves as an acquired hypercoagula

237 tients with hepatic fibrosis, HBV-associated liver cirrhosis (LC) patients and healthy controls (HC).

238 ined, especially in livers from HBV-infected liver cirrhosis (LC) patients.

239 with HCC in NCL to 571 patients with HCC in liver cirrhosis (LC) with respect to clinical and demogr

240 In the setting of liver cirrhosis (LC), profound hemostatic changes occur,

241 % subtype 1a, 30% Child-Pugh-Turcott [CPT]-B liver cirrhosis [LC], and 82% were treatment experienced

242 AS) of 0-4, 44 patients had an NAS of 5-8 or liver cirrhosis (LCI), 37 patients had F0-F1 fibrosis, a

243 Advanced stages of liver cirrhosis lead to a dramatically increased mortali

244 y readmission in patients with decompensated liver cirrhosis leads to an enormous burden on health ca

245 The development of hepatorenal syndrome in liver cirrhosis leads to an increased morbidity and mort

246 Angiogenesis in liver cirrhosis leads to splanchnic hyperemia, increased

247 Results A total of 42 participants with liver cirrhosis (mean age +/- standard deviation, 57 yea

248 Among patients with liver cirrhosis, mortality was 24.1%, corresponding to a

249 Using two liver cirrhosis mouse models induced by CCl4 or thioacet

250 20 muL of patient serum in HCC (n = 72) and liver cirrhosis (n = 58) showed that a unique trifucosyl

251 Fifteen patients with liver cirrhosis (nine men; mean age +/- standard deviati

252 o examine hemostasis in patients with stable liver cirrhosis (Non-ACLF) and in acute-on-chronic liver

253 nsion, with splenomegaly and symptoms of the liver cirrhosis occurred (thrombocytopenia, collateral v

254 Liver cirrhosis occurs as a consequence of many chronic

255 A pilot study of fucosylation in liver cirrhosis of the HCV and NASH etiologies confirms

256 healthy individuals as well as patients with liver cirrhosis or acute myeloid leukemia.

257 ired hepatitis B virus infection will die of liver cirrhosis or hepatocellular carcinoma.

258 alcoholic steatohepatitis (NASH) and lead to liver cirrhosis or liver cancer.

259 rhosis, the cumulative risk of being free of liver cirrhosis or liver-related events was 81.9% and 64

260 without evidence of clinical liver disease, liver cirrhosis, or alcohol abuse.

261 A levels were up-regulated 2.5-fold in human liver cirrhosis patient samples.

262 els were found for a total of 1,012 genes in liver cirrhosis patients without and with HE, and HE-cha

263 Using liver tissues from liver cirrhosis patients, we observed up-regulation of t

264 n patient subgroups, including patients with liver cirrhosis, patients with non-variceal upper gastro

265 occlusion of MPV, 98 patients diagnosed with liver cirrhosis related thrombotic total occlusion of MP

266 r decompensation, and death in patients with liver cirrhosis related to HCV was markedly reduced afte

267 l techniques and clinical outcome of TIPS on liver cirrhosis-related thrombotic total occlusion of MP

268 vely, TIPS is safe and effective in treating liver cirrhosis-related thrombotic total occlusion of MP

269 (0.23-0.56) for hepatocellular carcinoma and liver cirrhosis, respectively, and an adjusted rate rati

270 sis were significant predictors of alcoholic liver cirrhosis risk in men and women, whereas civil sta

271 Conclusion In participants with liver cirrhosis, systolic dysfunction and elevated param

272 Approximately half of all deaths from liver cirrhosis, the tenth leading cause of mortality in

273 hy is a frequent and serious complication of liver cirrhosis; the pathophysiology of this complicatio

274 ality in patients with acutely decompensated liver cirrhosis, though determining CysC at day 3 did no

275 patient serum samples from individuals with liver cirrhosis to accurately detect a characteristic in

276 Patients with liver cirrhosis typically exhibit abnormal coagulation p

277 ne hundred and one consecutive patients with liver cirrhosis underwent neurological examination, MMSE

278 "Hispanic paradox" applies to patients with liver cirrhosis using a retrospective cohort of twenty 1

279 can be the dominant symptom of decompensated liver cirrhosis, varices and ulcerations in the upper ga

280 ver transplantation because of decompensated liver cirrhosis was admitted with acute anaemia and recu

281 Liver cirrhosis was already present in 62 patients at fi

282 s and into the ascites of 12 volunteers with liver cirrhosis was also studied with RT-qPCR.

283 Liver cirrhosis was confirmed via histologic analysis in

284 clinical, laboratory parameters, etiology of liver cirrhosis was determined along with the scores lik

285 ss-sectional analysis of adult patients with liver cirrhosis was done at Bugando Medical Centre.

286 Liver function of 113 patients with liver cirrhosis was prospectively investigated.

287 on Alcohol Abuse and Alcoholism showed that liver cirrhosis was the 12th leading cause of death in t

288 Patients with HCV GT3 infection and/or liver cirrhosis were excluded.

289 Patients with liver cirrhosis were excluded.

290 male and 81 female; mean age, 56 years) with liver cirrhosis were included.

291 Anti-gal antibodies in patients with liver cirrhosis were reduced in their ability to mediate

292 Nine patients with liver cirrhosis were studied in connection with a previo

293 he treated cohort had a higher prevalence of liver cirrhosis when compared with the untreated cohort

294 Conclusions: Patients with liver cirrhosis who had undergone LSSM-guided variceal s

295 , 60 years +/- 11 [standard deviation]) with liver cirrhosis who underwent evaluation for HCC with MR

296 ected with HBV genotypes B or C, and without liver cirrhosis, who had long-term follow-up at the Nati

297 for [3-Nty](-2) at pH 7.3 in serum sample of liver cirrhosis with MHE diseases.

298 3-Nty as a biomarker for early diagnosis of liver cirrhosis with MHE in patients.

299 3-Nty) as a biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy (MHE

300 34 control subjects and in 37 patients with liver cirrhosis without MHE and 23 with MHE.